Prelude Therapeutics Inc [PRLD] stock is trading at $0.80, up 17.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PRLD shares have gain 12.54% over the last week, with a monthly amount glided 7.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Prelude Therapeutics Inc [NASDAQ: PRLD] stock has seen the most recent analyst activity on September 19, 2024, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, Barclays downgraded its rating to Underweight on June 20, 2024, and kept the price target unchanged to $3. On March 13, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $7 on the stock. H.C. Wainwright downgraded its rating to a Neutral but stick to its price target of $5 on February 20, 2024. Morgan Stanley downgraded its rating to a Underweight and reduced its price target to $4 on December 19, 2023. BofA Securities downgraded its rating to Underperform for this stock on November 21, 2022, and downed its price target to $6. In a note dated September 09, 2022, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $19 to $11.
Prelude Therapeutics Inc [PRLD] stock has fluctuated between $0.63 and $6.80 over the past year. Currently, Wall Street analysts expect the stock to reach $6.25 within the next 12 months. Prelude Therapeutics Inc [NASDAQ: PRLD] shares were valued at $0.80 at the most recent close of the market. An investor can expect a potential return of 681.25% based on the average PRLD price forecast.
Analyzing the PRLD fundamentals
Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -19.96%, Pretax Profit Margin comes in at -18.17%, and Net Profit Margin reading is -18.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.75 and Total Capital is -0.93. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7465 points at the first support level, and at 0.6932 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8465, and for the 2nd resistance point, it is at 0.8932.
Ratios To Look Out For
For context, Prelude Therapeutics Inc’s Current Ratio is 5.30. Also, the Quick Ratio is 5.30, while the Cash Ratio stands at 0.49. Considering the valuation of this stock, the price to sales ratio is 7.77, the price to book ratio is 0.34.
Transactions by insiders
Recent insider trading involved Combs Andrew, Chief Chemistry Officer, that happened on Mar 25 ’25 when 100000.0 shares were purchased. CEO, Vaddi Krishna completed a deal on Mar 25 ’25 to buy 0.68 million shares. Meanwhile, CEO Vaddi Krishna bought 15000.0 shares on Mar 21 ’25.
